Type 1 Diabetes Mellitus Clinical Trial
Official title:
Influence of Sucrose-free Diet or Sucrose-added Diet on Glucose Variability in Patients With Type 1 Diabetes
Verified date | September 2018 |
Source | Universidade Federal do Rio de Janeiro |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
BACKGROUND: The treatment with continuous glucose monitoring system (CGMS) offers improved
glycemic control for patients with type 1 diabetes. However, patients with type 1 diabetes
usually intake foods with sugar, even without hypoglycemic episodes, and the use of advanced
carbohydrate counting method may increase the calories and carbohydrate intake.
OBJECTIVE: To evaluate and compare the influence of sucrose-free diet or sucrose-added diet
on glucose variability in patients with type 1 diabetes.
METHODS: The study was a simple-blind, two-way crossover design in which patients with type 1
diabetes will receive a control diet (a diet with a little quantity of sugars) or test diet
(with foods containing moderate quantity of sucrose in composition) during two-days each.
During the intervention, all foods and drinks intake will have to be documented to allow
quantitative estimation of dietary intake, to verify adherence to the diets. After one-week,
each patient will return for download CGMS.
PURPOSE: The research proposal adds knowledge about the glucose variability in patients with
type 1 diabetes who use foods with sugar in theirs habitual dietary intake.
Status | Completed |
Enrollment | 10 |
Est. completion date | January 1, 2018 |
Est. primary completion date | July 31, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Type 1 diabetes ( = three years after diagnosis) - Adults - Using basal-bolus regimen with multiple insulin injections with long-acting insulin analogues (glargine, detemir, or degludec) combined with a short-acting analogs (aspart, lispro or glulisina) OR Continuous subcutaneous insulin infusion Exclusion Criteria: - Smokers - Drinkers - Use of exogenous hormone (with the exception of insulin) - Use of antibiotics, anti-inflammatories or oral antidiabetics pharmacotherapy - Diagnosis of nephropathy (Creatinine clearance <90mL/min/1,73m2) - Gastroparesis symptoms - Celiac disease - Hypothyroidism or hyperthyroidism - Other types of diabetes family history |
Country | Name | City | State |
---|---|---|---|
Brazil | Clementino Fraga Filho University Hospital of Rio de Janeiro | Rio de Janeiro |
Lead Sponsor | Collaborator |
---|---|
Universidade Federal do Rio de Janeiro |
Brazil,
Souto DL, Dantas JR, Oliveira MMDS, Rosado EL, Luiz RR, Zajdenverg L, Rodacki M. Does sucrose affect the glucose variability in patients with type 1 diabetes? A pilot crossover clinical study. Nutrition. 2018 Jun 8;55-56:179-184. doi: 10.1016/j.nut.2018.0 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Compare the intraday and interday glucose variability effect of sucrose-free with a sucrose-free diet for patients with type 1 diabetes. | Intraday and interday glucose variability will be evaluated by the following indexes: CONGA: continuous overall net glycemic action (mmol/L); MAGE: mean amplitude of glycemic excursion (mmol/L); MODD: mean of daily diferences (mmol/L). |
Through study completion, an average of 1 year | |
Secondary | Evaluate the intraday glycemic variability effect of foods containing different macronutrients quantity, through CONGA index. | CONGA: continuous overall net glycemic action (mmol/L | Through study completion, an average of 1 year | |
Secondary | Compare the intraday glycemic variability effect of sucrose-free diet and sucrose-added diet, through MAGE index, in patients with type 1 diabetes | MAGE: mean amplitude of glycemic excursion (mmol/L) | Through study completion, an average of 1 year | |
Secondary | Compare the interday glycemic variability effect of sucrose-free diet and sucrose-added diet, through MODD index, in patients with type 1 diabetes | MODD: mean of daily diferences (mmol/L | Through study completion, an average of 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04476472 -
Omnipod Horizon™ Automated Glucose Control System Preschool Cohort
|
N/A | |
Completed |
NCT03635437 -
Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes
|
Phase 1/Phase 2 | |
Completed |
NCT04909580 -
Decision Coaching for Youth and Parents Considering Insulin Delivery Methods for Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT00679042 -
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
|
Phase 3 | |
Completed |
NCT03293082 -
Preschool CGM Use and Glucose Variability in Type 1 Diabetes
|
N/A | |
Completed |
NCT04016662 -
Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D)
|
Phase 4 | |
Completed |
NCT02527265 -
Afrezza Safety and Pharmacokinetics Study in Pediatric Patients
|
Phase 2 | |
Completed |
NCT03738865 -
G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes
|
Phase 3 | |
Completed |
NCT03240432 -
Wireless Innovation for Seniors With Diabetes Mellitus
|
N/A | |
Completed |
NCT03168867 -
Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms)
|
N/A | |
Completed |
NCT03674281 -
The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System
|
N/A | |
Completed |
NCT03669770 -
Ultrasound Classification and Grading of Lipohypertrophy and Its Impact on Glucose Variability in Type 1 Diabetes
|
||
Recruiting |
NCT03682640 -
Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes
|
Phase 2 | |
Recruiting |
NCT04096794 -
Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
|
||
Completed |
NCT02882737 -
The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus
|
N/A | |
Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Completed |
NCT02596204 -
Diabetes Care Transformation: Diabetes Data Registry and Intensive Remote Monitoring
|
N/A | |
Completed |
NCT02558491 -
Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM
|
N/A | |
Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Completed |
NCT02562313 -
A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog®
|
Phase 1 |